Constitutive activation and endocytosis of the complement factor 5a receptor: Evidence for multiple activated conformations of a G protein-coupled receptor

Traffic

Volumn 3, Issue 12, 2002, Pages 866-877

  Whistler, Jennifer L ^a   Gerber, Basil O ^d   Meng, Elaine C ^b   Baranski, Thomas J ^e   von Zastrow, Mark ^b,c   Bourne, Henry R ^b  

^a UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arrestin; C5a; Constitutive activation; Endocytosis

Indexed keywords

BETA ARRESTIN; COMPLEMENT COMPONENT C5; COMPLEMENT RECEPTOR; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; BIOTIN; COMPLEMENT COMPONENT C5A RECEPTOR; GREEN FLUORESCENT PROTEIN; LEUKOCYTE ANTIGEN; LIGAND; PERTUSSIS TOXIN; PHOTOPROTEIN; RETINA S ANTIGEN;

ANIMAL CELL; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENDOCYTOSIS; GENE CONSTRUCT; GENE MUTATION; GENETIC CONSERVATION; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; ANIMAL; ARTICLE; CELL LINE; CELL MEMBRANE; CELL STRAIN COS1; CHEMICAL STRUCTURE; DOSE RESPONSE; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; METABOLISM; MUTATION; PHENOTYPE; PROTEIN BINDING; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION; TIME;

ANIMALS; ANTIGENS, CD; ARRESTIN; BIOTIN; CELL LINE; CELL MEMBRANE; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; GREEN FLUORESCENT PROTEINS; GTP-BINDING PROTEINS; HUMANS; LIGANDS; LUMINESCENT PROTEINS; MICROSCOPY, FLUORESCENCE; MODELS, MOLECULAR; MUTATION; PERTUSSIS TOXIN; PHENOTYPE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 0036898466     PISSN: 13989219     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0854.2002.31203.x     Document Type: Review

References (52)

1. Hamm HE. The many faces of G protein signaling. J Biol Chem 1998;273:669-672.
2. Bockaert J, Pin JP. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J 1999;18:1723-1729.
3. Baldwin JM, Schertler GF, Unger VM. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J Mol Biol 1997;272:144-164.
4. Josefsson LG. Evidence for kinship between diverse G-protein coupled receptors. Gene 1999;239:333-340.
5. Price LA, Kajkowski EM, Hadcock JR, Ozenberger BA, Pausch MH. Functional coupling of a mammalian somatostatin receptor to the yeast pheromone response pathway. Mol Cell Biol 1995;15:6188-6195.
6. Price LA, Strnad J, Pausch MH, Hadcock JR. Pharmacological characterization of the rat A2a adenosine receptor functionally coupled to the yeast pheromone response pathway. Mol Pharmacol 1996;60:829-837
7. Erickson JR, Wu JJ, Goddard JG, Tigyi G, Kawanishi K, Tomei LD, Kiefer MC. Edg-2/Vzg-1 couples to the yeast pheromone response pathway selectively in response to lysophosphatidic acid. J Biol Chem 1998;273:1606-1510.
8. Bourne HR. How receptors talk to trimeric G proteins. Curr Opin Cell Biol 1997;9:134-142.
9. Horn F, Weare J, Beukers MW, Horsch S, Bairoch A, Chen W, Edvardsen, O, Campagne, F, Vriend G. GPCRDB: an information system for G protein-coupled receptors. Nucl Acids Res 1998:26:275-279.
10. Kenakin T. Pharmacological proteus? Trends Pharmacol Sci 1995;16:256-258.
11. Leff P, Scaramellini C, Law C, McKechnie K. A three-state receptor model of agonist action. Trends Pharmacol Sci 1997;18:355-362.
12. Clark RB, Knoll BJ, Barber R. Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol Sci 1999:20:279-286.
13. Schwartz TW, Rosenkilde MM. Is there a 'lock' for all agonist 'keys' in 7TM receptors? Trends Pharmacol Sci 1996;17:213-216.
14. Cheung AH, Dixon RA, Hill WS, Sigal IS, Strader CD. Separation of the structural requirements for agonist-promoted activation and sequestration of the beta-adrenergic receptor. Mol Pharmacol 1990;37:775-779.
15. Gether U, Lin S, Kobilka BK. Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. J Biol Chem 1995;270:28268-28275.
16. Seifert R, Gether U, Wenzel-Seifert K, Kobilka BK. Effects of guanine, inosine, and xanthine nucleotides on beta (2)-adrenergic receptor/G (s) interactions: evidence for multiple receptor conformations. Mol Pharmacol 1999;56:348-358.
17. Hunyady L, Bor M, Balla T, Catt KJ. Identification of a cytoplasmic Ser-Thr-Leu motif that determines agonist-induced internalization of the AT1 angiotensin receptor. J Biol Chem 1994;269:31378-31382.
18. Bennett TA, Maestas DC, Prossnitz ER. Arrestin binding to the G protein-coupled N-formyl peptide receptor is regulated by the conserved 'DRY' sequence. J Biol Chem 2000:275:24590-24594.
19. Rodriguez-Frade JM, Vila-Coro AJ, Martin A, Nieto M, Sanchez-Madrid F, Proudfoot AE, Wells TN, Martinez AC, Mellado M. Similarities and differences in RANTES- and (AOP)-RANTES-triggered signals: implications for chemotaxis. J Cell Biol 1999;144:755-765.
20. Elsner J, Mack M, Bruhl H, Dulkys Y, Kimmig D, Simmons G, Clapham PR, Schlondorff D, Kapp A, Wells TN, Proudfoot AE. Differential activation of CC chemokine receptors by AOP-RANTES. J Biol Chem 2000;275:7787-7794.
21. Bardi G, Lipp M, Baggiolini M, Loetscher P. The T cell chemokine receptor CCR7 is internalized on stimulation with ELC, but not with SLC. Eur J Immunol 2001;31:3291-3297
22. Blanpain C, Vanderwinden JM, Cihak J, Wittamer V, Le Poul E, Issafras H, Stangassinger M, Vassart G, Marullo S, Schlondorff D, Parmerrtier M, Mack M. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell 2002;13:723-737.
23. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans CJ, von Zastrow M. Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 1996;271:19021-19024.
24. Whistler JL, Chuang HH, Chu P, January LY, von Zastrow M. Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 1999;23:737-746.
25. Baranski TJ, Herzmark P, Lichtarge O, Gerber BO, Trueheart J, Meng EC, Iiri T, Sheikh SP, Bourne HR. C5a receptor activation. Genetic identification of critical residues in four transmembrane helices. J Biol Chem 1999;274:15757-15765.
26. Mollison KW, Mandecki W, Zuiderweg ER, Fayer L, Fey TA, Krause RA, Conway RG, Miller L, Edalji RP, Shallcross MA. Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc Natl Acad Sci USA 1989;86:292-296.
27. Raffetseder U, Roper D, Mery L, Gietz C, Klos A, Grotzinger J, Wollmer A, Boulay F, Kohl J, Bautsch W. Site-directed mutagenesis of conserved charged residues in the helical region of the human C5a receptor. Arg206 determines high-affinity binding sites of C5a receptor. Eur J Biochem 1996;235:82-90.
28. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000;21:90-113.
29. Samama P, Cotecchia S, Costa T, Lefkowitz RJ. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 1993;268:4625-4636.
30. Siciliano SJ, Rollins TE, DeMartino J, Konteatis Z, Malkowitz L, Van Riper G, Bondy S, Rosen H, Springer MS. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci USA 1994,91:1214-1218.
31. Whistler JL, von Zastrow M. Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci USA 1998;95:9914-9919.
32. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, Caron MG, Lefkowitz RJ. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999;283:655-661.
33. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ, Lefkowitz RJ. Beta-arrestin 2, a receptor-regulated MAPK scaffold for the activation of JNK3. Science 2000;290:1574-1577.
34. Goodman OB Jr, Krupnick JG, Santini F, Gurevich VV, Penn RB, Gagnon AW, Keen JH, Benovic JL. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2- adrenergic receptor. Nature 1996;383:447-450.
35. Barak LS, Ferguson SS, Zhang J, Caron MG. A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem 1997;272:27497-27500.
36. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG. Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J Biol Chem 1999;274:32248-32257.
37. Zhang J, Barak LS, Anborgh PH, Laporte SA, Caron MG, Ferguson SS. Cellular trafficking of G protein-coupled receptor/beta-arrestin endocytic complexes. J Biol Chem 1999;274:10999-11006.
38. Whistler JL, Tsao P, von Zastrow M. A phosphorylation-regulated brake mechanism controls the initial endocytosis of opioid receptors but is not required for post-endocytic sorting to lysosomes. J Biol Chem 2001;276:34331-34338.
39. Prehoda KE, Scott JA, Mullins RD, Lim WA. Integration of multiple signals through cooperative regulation of the N-WASP-Arp2/3 complex. Science 2000;290:801-806.
40. Mayer ML, Westbrook GL, Guthrie PB. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature 1984;309:261-263.
41. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 1984;307:462-465.
42. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-937.
43. Burger HG. Selective oestrogen receptor modulators. Horm Res 2000;53:25-29.
44. Lefkowitz RJ. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem 1998;273:18677-18680.
45. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 1994;12:593-633.
46. Corvilain B, Van Sande J, Dumont JE, Vassart G. Somatic and germline mutations of the TSH receptor and thyroid diseases. Clin Endocrinol (Oxf) 2001;55:143-158.
47. Kosugi S, Van Dop C, Geffner ME, Rabl W, Carel JC, Chaussain JL, Mori T, Merendino JJ Jr, Shenker A. Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty. Hum Mol Genet 1995;4:183-188.
48. Barak LS, Oakley RH, Laporte SA, Caron MG. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci USA 2001;98:93-98.
49. Garcia PD, Onrust R, Bell SM, Sakmar TP, Bourne HR. Transducin-alpha C-terminal mutations prevent activation by rhodopsin: a new assay using recombinant proteins expressed in cultured cells. EMBO J 1995;14:4460-4469.
50. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000;289:739-745.
51. Bower MJ, Cohen FE, Dunbrack RL Jr. Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. J Mol Biol 1997;267:1268-1282.
52. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997;18:2714-2723.